Interest in predictive testing for Parkinson's disease:: Impact of neuroprotective therapy
Interest in predictive testing for Parkinson's disease:: Impact of neuroprotective therapy
复制标题
DOI：
10.1016/j.parkreldis.2007.02.010
复制
发表时间：
2007-01-01
影响因子：
4.1
通讯作者：
Siderowf, A.
中科院分区：
文献类型：
--
作者：
Dahodwala, N.;Connolly, J.;Siderowf, A.
随着帕金森病（PD）的预测性测试变得可用，了解这种测试将用于谁将是很重要的。为了解决这个问题，我们进行了一次邮件调查的138个一级亲属的PD患者。在没有治疗的情况下，60%的人报告说他们“肯定”或“可能”对预测性测试感兴趣。在临床试验中，这一数字增加到71%（p = 0.04），当神经保护治疗可用时，兴趣增加到90%（p < 0.001）。在缺乏有效治疗的情况下，对PD的预测性测试的兴趣是中等的，当提供临床试验参与和神经保护治疗时，这种兴趣会显著增加。(c)2007爱思唯尔有限公司保留所有权利。
As predictive testing for Parkinson's disease (PD) becomes available, it will be important to understand in whom such testing will be used. To address this issue, we conducted a mail Survey of 138 first-degree relatives of PD patients. In the absence of treatment, 60% reported that they would either "definitely" or "probably" be interested in predictive testing. In the setting of a clinical trial, this number increased to 71% (p = 0.04) and when neuroprotective therapy is available, interest increased to 90% (p < 0.001). Interest in predictive testing for PD is moderate in the absence of effective therapy, and goes Lip significantly when both clinical trial participation and neuroprotective therapy are offered. (c) 2007 Elsevier Ltd. All rights reserved.